The company enrolled 551 obese patients at multiple clinical sites in the US for a six-month, randomized, placebo-controlled dose ranging study. The study is designed to evaluate three different doses of PYY3-36 Nasal Spray compared to placebo and sibutramine (Meridia), a commercially available oral weight loss drug, with the primary endpoint being weight loss.
Gordon Brandt, president of Nastech, said: “If successful, PYY Nasal Spray would offer a patient-friendly product to promote weight loss.”